Barclays PLC Grows Stake in Savara Inc (NASDAQ:SVRA)

Barclays PLC lifted its stake in shares of Savara Inc (NASDAQ:SVRA) by 217.5% in the third quarter, Holdings Channel reports. The firm owned 231,005 shares of the company’s stock after buying an additional 158,244 shares during the period. Barclays PLC’s holdings in Savara were worth $979,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Wellington Management Group LLP grew its stake in Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. State Street Corp grew its stake in Savara by 15.7% during the 3rd quarter. State Street Corp now owns 4,138,276 shares of the company’s stock valued at $17,546,000 after acquiring an additional 560,242 shares in the last quarter. Verition Fund Management LLC grew its stake in Savara by 83.5% during the 3rd quarter. Verition Fund Management LLC now owns 114,495 shares of the company’s stock valued at $485,000 after acquiring an additional 52,084 shares in the last quarter. Vestal Point Capital LP grew its stake in Savara by 24.7% during the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after acquiring an additional 1,600,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after acquiring an additional 6,141 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 2.2 %

Shares of NASDAQ:SVRA opened at $3.08 on Tuesday. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70. The company’s 50 day moving average is $3.41 and its two-hundred day moving average is $3.95. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market cap of $528.59 million, a PE ratio of -7.16 and a beta of 0.92.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insider Activity at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.13% of the company’s stock.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Thursday, December 19th. HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Wells Fargo & Company started coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, Evercore ISI restated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $9.86.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.